» Articles » PMID: 12060571

Inhibition of Endogenous TRP1 Decreases Capacitative Ca2+ Entry and Attenuates Pulmonary Artery Smooth Muscle Cell Proliferation

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary vascular medial hypertrophy due to proliferation of pulmonary artery smooth muscle cells (PASMC) greatly contributes to the increased pulmonary vascular resistance in pulmonary hypertension patients. A rise in cytosolic free Ca2+ concentration ([Ca2+]cyt) is an important stimulus for cell growth in PASMC. Resting [Ca2+]cyt, intracellularly stored [Ca2+], capacitative Ca2+ entry (CCE), and store-operated Ca2+ currents (I(SOC)) are greater in proliferating human PASMC than in growth-arrested cells. Expression of TRP1, a transient receptor potential gene proposed to encode the channels responsible for CCE and I(SOC), was also upregulated in proliferating PASMC. Our aim was to determine if inhibition of endogenous TRP1 gene expression affects I(SOC) and CCE and regulates cell proliferation in human PASMC. Cells were treated with an antisense oligonucleotide (AS, for 24 h) specifically designed to cleave TRP1 mRNA and then returned to normal growth medium for 40 h before the experiments. Then, mRNA and protein expression of TRP1 was downregulated, and amplitudes of I(SOC) and CCE elicited by passive depletion of Ca2+ from the sarcoplasmic reticulum using cyclopiazonic acid were significantly reduced in the AS-treated PASMC compared with control. Furthermore, the rate of cell growth was decreased by 50% in AS-treated PASMC. These results indicate that TRP1 may encode a store-operated Ca2+ channel that plays a critical role in PASMC proliferation by regulating CCE and intracellular [Ca2+](cyt).

Citing Articles

Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.

Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J J Immunother Cancer. 2025; 13(1.

PMID: 39800374 PMC: 11749218. DOI: 10.1136/jitc-2024-010331.


Piezo1, a novel therapeutic target to treat pulmonary arterial hypertension.

Yang Q, Li X, Xing Y, Chen Y Front Physiol. 2023; 14:1084921.

PMID: 36776977 PMC: 9909334. DOI: 10.3389/fphys.2023.1084921.


Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca signaling.

Balistrieri A, Makino A, Yuan J Physiol Rev. 2022; 103(3):1827-1897.

PMID: 36422993 PMC: 10110735. DOI: 10.1152/physrev.00030.2021.


A narrative review of research advances in hypoxic pulmonary hypertension.

Chai T, Qiu C, Xian Z, Lu Y, Zeng Y, Li J Ann Transl Med. 2022; 10(4):230.

PMID: 35280399 PMC: 8908157. DOI: 10.21037/atm-22-259.


Role of Store-Operated Ca Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension.

Masson B, Montani D, Humbert M, Capuano V, Antigny F Biomolecules. 2021; 11(12).

PMID: 34944425 PMC: 8698435. DOI: 10.3390/biom11121781.